Skip to contentN
Neogenomics Inc
N
NEONeogenomics Inc Q3 2023 · 10-Q
Revenue$151.95M$151.95M+18.0% vs Q3 2022 Net Income-$18.52M-$18.52MN/M vs Q3 2022 EPS Diluted-$0.15-$0.15N/M vs Q3 2022 Gross Profit$62,311,000+27.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Neogenomics Inc · CIK 1077183 · Engraved from SEC EDGAR
Operating Cash Flowderived-$5,497,000N/M Free Cash Flowderived-$9,771,000N/M Margins · derivedGross margin41.0%+3.0 pt vs Q3 2022
Operating margin-15.9%+14.8 pt vs Q3 2022
Net margin-12.2%+16.4 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 6, 2023 · 37 d after period end